These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35050221)

  • 1. Electrocardiographic Characteristics and Their Correlation with Echocardiographic Alterations in Fabry Disease.
    Zada M; Lo Q; Trivedi SJ; Harapoz M; Boyd AC; Devine K; Sadick N; Tchan MC; Thomas L
    J Cardiovasc Dev Dis; 2022 Jan; 9(1):. PubMed ID: 35050221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.
    Augusto JB; Johner N; Shah D; Nordin S; Knott KD; Rosmini S; Lau C; Alfarih M; Hughes R; Seraphim A; Vijapurapu R; Bhuva A; Lin L; Ojrzyńska N; Geberhiwot T; Captur G; Ramaswami U; Steeds RP; Kozor R; Hughes D; Moon JC; Namdar M
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):790-799. PubMed ID: 32514567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between electrocardiographic left ventricular hypertrophy criteria and echocardiographic mass in patients undergoing transcatheter aortic valve replacement.
    Sjöberg S; Sundh F; Schlegel T; Maynard C; Rück A; Wagner G; Ugander M
    J Electrocardiol; 2015; 48(4):630-6. PubMed ID: 25865909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V; Okin PM; de Simone G; Bella JN; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cornell product in an electrocardiogram is related to reduced LV regional wall motion.
    Ishikawa J; Yamanaka Y; Watanabe S; Toba A; Harada K
    Hypertens Res; 2019 Apr; 42(4):541-548. PubMed ID: 30542082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanical dispersion in Fabry disease assessed with speckle tracking echocardiography.
    Cianciulli TF; Saccheri MC; Rísolo MA; Lax JA; Méndez RJ; Morita LA; Beck MA; Kazelián LR
    Echocardiography; 2020 Feb; 37(2):293-301. PubMed ID: 31957094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements.
    Shanks M; Thompson RB; Paterson ID; Putko B; Khan A; Chan A; Becher H; Oudit GY
    J Am Soc Echocardiogr; 2013 Dec; 26(12):1407-14. PubMed ID: 24125876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early cardiac changes in children with anderson-fabry disease.
    Havranek S; Linhart A; Urbanova Z; Ramaswami U
    JIMD Rep; 2013; 11():53-64. PubMed ID: 23546814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
    Motwani M; Banypersad S; Woolfson P; Waldek S
    Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrocardiographic criteria for left ventricular hypertrophy in aortic valve stenosis: Correlation with echocardiographic parameters.
    Bula K; Ćmiel A; Sejud M; Sobczyk K; Ryszkiewicz S; Szydło K; Wita M; Mizia-Stec K
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12645. PubMed ID: 30896064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrocardiogram analysis in Anderson-Fabry disease: a valuable tool for progressive phenotypic expression tracking.
    Parisi V; Baldassarre R; Ferrara V; Ditaranto R; Barlocco F; Lillo R; Re F; Marchi G; Chiti C; Di Nicola F; Catalano C; Barile L; Schiavo MA; Ponziani A; Saturi G; Caponetti AG; Berardini A; Graziosi M; Pasquale F; Salamon I; Ferracin M; Nardi E; Capelli I; Girelli D; Gimeno Blanes JR; Biffi M; Galiè N; Olivotto I; Graziani F; Biagini E
    Front Cardiovasc Med; 2023; 10():1184361. PubMed ID: 37416917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ECG is an inefficient screening-tool for left ventricular hypertrophy in normotensive African children population.
    Di Gioia G; Creta A; Campanale CM; Fittipaldi M; Giorgino R; Quintarelli F; Satriano U; Cruciani A; Antinolfi V; Di Berardino S; Costanzo D; Bettini R; Mangiameli G; Caricato M; Mottini G
    PeerJ; 2016; 4():e2439. PubMed ID: 27651998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrocardiographic strain pattern in children with left ventricular hypertrophy: a marker of ventricular dysfunction.
    Shah N; Chintala K; Aggarwal S
    Pediatr Cardiol; 2010 Aug; 31(6):800-6. PubMed ID: 20422173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and prevalence of cardiac abnormalities on electro- and echocardiography in a large cohort of patients with mitochondrial disease.
    Hendrix CLF; van den Heuvel FMA; Rodwell L; Timmermans J; Nijveldt R; Janssen MCH; Saris CGJ
    Mol Genet Metab; 2022 Jul; 136(3):219-225. PubMed ID: 35659503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease.
    Namdar M; Steffel J; Jetzer S; Schmied C; Hürlimann D; Camici GG; Bayrak F; Ricciardi D; Rao JY; de Asmundis C; Chierchia GB; Sarkozy A; Lüscher TF; Jenni R; Duru F; Brugada P
    Am J Cardiol; 2012 Feb; 109(4):587-93. PubMed ID: 22105784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Fabry Disease cardiac involvement according to longitudinal strain, cardiometabolic exercise test, and T1 mapping.
    Réant P; Testet E; Reynaud A; Bourque C; Michaud M; Rooryck C; Goizet C; Lacombe D; de-Précigout V; Peyrou J; Cochet H; Lafitte S
    Int J Cardiovasc Imaging; 2020 Jul; 36(7):1333-1342. PubMed ID: 32385539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective investigation to establish new screening approach for the detection of patients at high risk of Fabry disease in male left ventricular hypertrophy patients.
    Kubo T; Amano M; Takashio S; Okumura T; Yamamoto S; Nabeta T; Oikawa M; Kurisu S; Ochi Y; Sugiura K; Baba Y; Kuroiwa H; Hirota T; Yamasaki N; Ishii S; Nochioka K; Takeishi Y; Yasuda S; Tsujita K; Izumi C; Kitaoka H
    J Cardiol; 2022 Oct; 80(4):325-331. PubMed ID: 35643740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of isolated papillary muscle hypertrophy: A comparison of left ventricular hypertrophy diagnosed using electrocardiography vs echocardiography.
    Nomura N; Tani T; Konda T; Kim K; Kitai T; Nomoto N; Suganuma N; Nakamura H; Sumida T; Fujii Y; Kawai J; Kaji S; Furukawa Y
    Echocardiography; 2018 Mar; 35(3):292-300. PubMed ID: 29280520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test characteristics of electrocardiography for detection of left ventricular hypertrophy in asymptomatic emergency department patients with hypertension.
    Mahn JJ; Dubey E; Brody A; Welch R; Zalenski R; Flack JM; Ference B; Levy PD
    Acad Emerg Med; 2014 Sep; 21(9):996-1002. PubMed ID: 25269580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.